Exelixis Inc (FRA:EX9)
€ 32.75 -0.25 (-0.76%) Market Cap: 9.53 Bil Enterprise Value: 8.45 Bil PE Ratio: 21.93 PB Ratio: 4.30 GF Score: 81/100

Exelixis Inc at Goldman Sachs Healthcare Conference Transcript

Jun 13, 2023 / 11:00PM GMT
Release Date Price: €17.56 (-0.85%)
Stephen Rogers Sloan
Goldman Sachs Group, Inc., Research Division - Research Analyst

All right. It looks like we're started. Thanks, everyone, for joining. I'm Stephen Sloan, an analyst on the biopharma research team here at Goldman. And I'm happy to present or do a fireside chat with Exelixis. We have Andrew Peters here, Senior Vice President and Head of Strategy. I know on the schedule it said Michael Morrissey, but we have Andrew Peters, which we're very happy to host.

And so to kick this off, for those of you who might not be as familiar with Andrew, do you want to give a bit of background on yourself? This is very much in line with what Chris Shibutani would be doing. So let's kick it off here.

Andrew Ross Peters
Exelixis, Inc. - SVP of Strategy

Yes. No, happy to be here. Thanks for the invite. And before I begin, likely to be making some forward-looking statements today. So please see our relevant SEC filings for appropriate disclosures about the risk to our business, et cetera.

So yes, so I've been at Exelixis since about 2018 or so

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot